Thalassemia Major Clinical Trial
Official title:
Evaluation of Nutritional Status in Patients With Thalassemia Major in Assiut University Children Hospital
| NCT number | NCT03161899 |
| Other study ID # | ENST |
| Secondary ID | |
| Status | Completed |
| Phase | |
| First received | |
| Last updated | |
| Start date | December 15, 2018 |
| Est. completion date | July 20, 2020 |
| Verified date | July 2020 |
| Source | Assiut University |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
Thalassemia is a blood disorder passed down through families in which the body makes an
abnormal form of hemoglobin. There are 2 main types of thalassemia; Alpha & Beta thalassemia.
Alpha thalassemia: occurs when a gene or genes related to the alpha globin protein are
missing or mutated.
Beta-thalassemia syndromes are a group of hereditary blood disorders characterized by reduced
or absent beta globin chain synthesis. Beta-thalassemias can be classified into:
Silent carrier: completely asymptomatic with normal hematological parameters.
Beta-thalassaemia minor (beta-thalassaemia trait): usually asymptomatic; diagnosis is made
during a work-up for mild anemia.
Beta-thalassaemia intermedia: usually a similar presentation to beta-thalassaemia major;
symptoms are usually less pronounced and the course is usually more insidious.
Beta-thalassaemia major : In which there is complete absence of hemoglobin A
| Status | Completed |
| Enrollment | 246 |
| Est. completion date | July 20, 2020 |
| Est. primary completion date | May 24, 2020 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 6 Years to 14 Years |
| Eligibility |
Inclusion Criteria: - patients diagnosed to have thalassemia Exclusion Criteria: - patient with any underlaying systemic diseases other than B thalassemia major. |
| Country | Name | City | State |
|---|---|---|---|
| Egypt | Asmaa Refaat Abdelmonem | Assiut |
| Lead Sponsor | Collaborator |
|---|---|
| Assiut University |
Egypt,
Fung EB. Nutritional deficiencies in patients with thalassemia. Ann N Y Acad Sci. 2010 Aug;1202:188-96. doi: 10.1111/j.1749-6632.2010.05578.x. — View Citation
Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis. 2010 May 21;5:11. doi: 10.1186/1750-1172-5-11. Review. — View Citation
Soliman AT, El-Matary W, Fattah MM, Nasr IS, El Alaily RK, Thabet MA. The effect of high-calorie diet on nutritional parameters of children with beta-thalassaemia major. Clin Nutr. 2004 Oct;23(5):1153-8. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | percentage of malnutrition | prevalence of malnutrition among thalassemic children attending assiut university children hospital | 12 month | |
| Secondary | aetiology poor growth | determination of the most common causes responsible for poor growth seen in thalassemic patients | 12 month | |
| Secondary | decrease morbidity | decrease morbidity by providing possible strategies for early prevention of the problem of poor growth occurring in patients with thalassemia major | 18 month |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02559648 -
Denosumab vs Placebo in Patients With Thalassemia Major and Osteoporosis
|
Phase 2 | |
| Recruiting |
NCT02126046 -
Unrelated Umbilical Cord Blood Following HLA-haploidentical Hematopoietic Stem Cell Transplantation in Patients With β-thalassemia Major
|
N/A | |
| Completed |
NCT01125254 -
Amlodipine Use in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major
|
Phase 2/Phase 3 | |
| Terminated |
NCT00034528 -
Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia
|
Phase 2 | |
| Completed |
NCT00733811 -
Efficacy Study of the Use of Sequential DFP-DFO Versus DFP
|
Phase 4 | |
| Enrolling by invitation |
NCT02986698 -
In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM)
|
Phase 1 | |
| Not yet recruiting |
NCT06026839 -
Longitudinal Study on the QoL of Pediatric Patients After HSCT and Its Influencing Factors
|
||
| Terminated |
NCT00007072 -
Phase II Study of Azacitidine and Phenylbutyrate in Patients With Thalassemia Major
|
Phase 2 | |
| Completed |
NCT04292314 -
Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major Thalassemia
|
Phase 2/Phase 3 | |
| Completed |
NCT02049450 -
Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia.
|
Phase 2 | |
| Active, not recruiting |
NCT04523376 -
Pilot Study PBSCT With TCRab Depletion For Hemoglobinopathies
|
N/A | |
| Completed |
NCT03992001 -
Impact of the Preparation Method of Red Cell Concentrates on Transfusion Indices in Thalassemic Patients
|
Phase 4 | |
| Not yet recruiting |
NCT05777733 -
NAC Effect on Iron Overload and Blood Transfusion in β-thalassemia Major
|
Phase 1 | |
| Completed |
NCT01241357 -
High-Tc Susceptometer to Monitor Transfusional Iron Overload
|
Phase 2 | |
| Completed |
NCT00749515 -
Pilot Study for Patients With Poor Response to Deferasirox
|
Phase 4 | |
| Completed |
NCT04260516 -
The Effect of N-acetylcysteine on Oxidative Stress Status and Iron Overload in Thalassemia Major
|
Phase 1 | |
| Recruiting |
NCT02307786 -
Long Term Outcomes in β Thalassemia Major
|
N/A | |
| Not yet recruiting |
NCT01323608 -
The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study
|
Phase 4 | |
| Completed |
NCT00005893 -
Study of Allogeneic Bone Marrow Transplantation Using Matched, Related Donors in Patients With Nonmalignant Hematologic Disorders
|
N/A | |
| Recruiting |
NCT06137079 -
"Iron Overload and Endocrinological Diseases"
|